Human CCL17/TARC Quantikine ELISA Kit

Catalog # Availability Size / Price Qty
PDDN00
SDN00
DDN00
Control Products Available
Human CCL17/TARC ELISA Calibrator Diluent RD5-5 Standard Curve
3 Images
Product Details
Procedure
Citations (35)
FAQs
Supplemental Products
Reviews (1)

Human CCL17/TARC Quantikine ELISA Kit Summary

Assay Type
Solid Phase Sandwich ELISA
Format
96-well strip plate
Assay Length
3.5 hours
Sample Type & Volume Required Per Well
Cell Culture Supernates (50 uL), Serum (50 uL), EDTA Plasma (50 uL), Heparin Plasma (50 uL)
Sensitivity
7 pg/mL
Assay Range
31.2 - 2,000 pg/mL (Cell Culture Supernates, Serum, EDTA Plasma, Heparin Plasma)
Specificity
Natural and recombinant human TARC
Cross-reactivity
< 0.5% cross-reactivity observed with available related molecules.< 50% cross-species reactivity observed with species tested.
Interference
No significant interference observed with available related molecules.

Product Summary

The Quantikine Human TARC Immunoassay kit is a 3.5 hour solid phase ELISA designed to measure TARC in cell culture supernates, serum, and plasma. It contains E. coli-expressed recombinant human TARC and antibodies raised against the recombinant factor. It has been shown to accurately quantitate recombinant human TARC. Results obtained using natural human TARC showed linear curves that were parallel to the standard curves obtained using the recombinant Quantikine kit standards. These results indicate that this kit can be used to determine relative mass values for natural human TARC.

Precision

Intra-Assay Precision (Precision within an assay) Three samples of known concentration were tested on one plate to assess intra-assay precision
Inter-Assay Precision (Precision between assays) Three samples of known concentration were tested in separate assays to assess inter-assay precision

Serum, EDTA Plasma, Heparin Plasma

Intra-Assay Precision Inter-Assay Precision
Sample 1 2 3 1 2 3
n 20 20 20 40 40 40
Mean 87 600 1107 98 616 1178
Standard Deviation 6.2 13.7 29.9 8.9 50.7 88.8
CV% 7.1 2.3 2.7 9.1 8.2 7.5

Cell Culture Supernates

Intra-Assay Precision Inter-Assay Precision
Sample 1 2 3 1 2 3
n 20 20 20 40 40 40
Mean 88 504 1001 89 540 1033
Standard Deviation 4.1 21.7 27.2 8.3 38.9 71.7
CV% 4.7 4.3 2.7 9.3 7.2 6.9

Recovery

The recovery of TARC spiked to three different levels throughout the range of the assay in various matrices was evaluated.

Sample Type Average % Recovery Range %
Cell Culture Media (n=4) 95 88-104
EDTA Plasma (n=5) 102 86-111
Heparin Plasma (n=5) 98 86-107
Serum (n=5) 105 100-114

Linearity

To assess the linearity of the assay, samples containing or spiked with high concentrations of TARC were diluted with the appropriate Calibrator Diluent to produce samples with values within the dynamic range of the assay.
Human CCL17/TARC ELISA Linearity

Data Examples

Human CCL17/TARC ELISA Calibrator Diluent RD5-5 Standard Curve

Human CCL17/TARC ELISA Calibrator Diluent RD6Q Standard Curve

Product Datasheets

Preparation and Storage

Storage
Store the unopened product at 2 - 8 °C. Do not use past expiration date.

Background: CCL17/TARC

CCL17/TARC is a chemokine that interacts with CCR4 and CCR8 to induce the chemoattraction of activated Th2 cells, basophils, and NK cells. It is produced by thymic dendritic cells, lymph node dendritic cells, monocytes, CD4+ T cells, keratinocytes, fibroblasts, bronchial epithelial cells, and Reed-Sternberg cells. CCL17 promotes Th2 cell recruitment to sites of inflammation and induces platelet aggregation and degranulation.

Entrez Gene IDs:
6361 (Human); 20295 (Mouse)
Alternate Names:
ABCD-2; CC chemokine TARC; C-C motif chemokine 17; CCL17; chemokine (C-C motif) ligand 17; MGC138273; SCYA17; SCYA17MGC138271; small inducible cytokine subfamily A (Cys-Cys), member 17; Small-inducible cytokine A17; T cell-directed CC chemokine; TARC; TARCA-152E5.3; Thymus and activation-regulated chemokine
⚠ WARNING: This product can expose you to chemicals including N,N-Dimethylforamide, which is known to the State of California to cause cancer. For more information, go to www.P65Warnings.ca.gov.

Assay Procedure

Refer to the product for complete assay procedure.

Bring all reagents and samples to room temperature before use. It is recommended that all samples, standards, and controls be assayed in duplicate.
  1.   Prepare all reagents, standard dilutions, and samples as directed in the product insert.
  2.   Remove excess microplate strips from the plate frame, return them to the foil pouch containing the desiccant pack, and reseal.

  3. 100 µL Assay Diluent
  4.   Add 100 µL of Assay Diluent to each well.

  5. 50 µL Standard, Control, or Sample
  6.   Add 50 µL of Standard, control, or sample to each well. Cover with a plate sealer, and incubate at room temperature for 2 hours.
  7.   Aspirate each well and wash, repeating the process twice for a total of 3 washes.

  8. 200 µL Conjugate
  9.   Add 200 µL of Conjugate to each well. Cover with a new plate sealer, and incubate at room temperature for 1 hour.
  10.   Aspirate and wash 3 times.

  11. 200 µL Substrate Solution
  12.   Add 200 µL Substrate Solution to each well. Incubate at room temperature for 30 minutes. PROTECT FROM LIGHT.

  13. 50 µL Stop Solution
  14.   Add 50 µL of Stop Solution to each well. Read at 450 nm within 30 minutes. Set wavelength correction to 540 nm or 570 nm.

Citations for Human CCL17/TARC Quantikine ELISA Kit

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

35 Citations: Showing 1 - 10
Filter your results:

Filter by:

  1. miR-1291 Functions as a Potential Serum Biomarker for Bullous Pemphigoid
    Authors: L Qiu, L Zhang, R Qi, X Gao, H Chen, T Xiao
    Dis. Markers, 2020;2020(0):9505312.
    Species: Human
    Sample Types: Serum
  2. Mitochondrial fission-induced mtDNA stress promotes tumor-associated macrophage infiltration and HCC progression
    Authors: D Bao, J Zhao, X Zhou, Q Yang, Y Chen, J Zhu, P Yuan, J Yang, T Qin, S Wan, J Xing
    Oncogene, 2019;0(0):.
    Species: Human
    Sample Types: Cell Culture Supernates
  3. Changes in the Anti-Allergic Activities of Sesame by Bioconversion
    Authors: TD Jung, SI Choi, SH Choi, BY Cho, WS Sim,, SJ Lee, SJ Park, DB Kim, YC Kim, JH Lee, OH Lee
    Nutrients, 2018;10(2):.
    Species: Human
    Sample Types: Cell Culture Supernates
  4. Skin Barrier Recovery by Protease-Activated Receptor-2 Antagonist Lobaric Acid
    Authors: Jae Sung Hwang
    Biomol Ther (Seoul), 2016;24(5):529-35.
    Species: Human
    Sample Types: Cell Culture Supernates
  5. Expansion of activated regulatory T cells by myeloid-specific chemokines via an alternative pathway in CSF of bacterial meningitis patients.
    Authors: Shi G, Han J, Liu G, Hao Y, Ma Y, Li T, Wu X, Zhang H, Liu Y, Wang B, Kong Y, Zhou J, Zeng H
    Eur J Immunol, 2014;44(2):420-30.
    Species: Human
    Sample Types: Cell Culture Supernates
  6. Prognostic significance of pretreatment serum cytokines in classical Hodgkin lymphoma.
    Authors: Marri P, Hodge L, Maurer M, Ziesmer S, Slager S, Habermann T, Link B, Cerhan J, Novak A, Ansell S
    Clin Cancer Res, 2013;19(24):6812-9.
    Species: Human
    Sample Types: Serum
  7. BAFF/APRIL system in pediatric OMS: relation to severity, neuroinflammation, and immunotherapy.
    Authors: Pranzatelli, Michael, Tate, Elizabet, McGee, Nathan R, Travelstead, Anna L, Colliver, Jerry A, Ness, Jayne M, Ransohoff, Richard
    J Neuroinflammation, 2013;10(0):10.
    Species: Human
    Sample Types: Serum
  8. Regulatory T cells suppress T cell activation at the pathologic site of human visceral leishmaniasis.
    Authors: Rai AK, Thakur CP, Singh A
    PLoS ONE, 2012;7(2):e31551.
    Species: Human
    Sample Types: Serum
  9. Distinct roles for CCR4 and CXCR3 in the recruitment and positioning of regulatory T cells in the inflamed human liver.
    Authors: Oo YH, Weston CJ, Lalor PF, Curbishley SM, Withers DR, Reynolds GM, Shetty S, Harki J, Shaw JC, Eksteen B, Hubscher SG, Walker LS, Adams DH
    J. Immunol., 2010;184(6):2886-98.
  10. Mepolizumab as a corticosteroid-sparing agent in lymphocytic variant hypereosinophilic syndrome.
    Authors: Roufosse F, de Lavareille A, Schandene L, Cogan E, Georgelas A, Wagner L, Xi L, Raffeld M, Goldman M, Gleich GJ, Klion A
    J. Allergy Clin. Immunol., 2010;126(4):828-835.
    Species: Human
    Sample Types: Serum
  11. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas.
    Authors: Younes A, Bartlett NL, Leonard JP
    N. Engl. J. Med., 2010;363(19):1812-21.
    Species: Human
    Sample Types: Serum
  12. The imbalance in serum concentration of Th-1- and Th-2-derived chemokines as one of the factors involved in pathogenesis of atopic dermatitis.
    Authors: Narbutt J, Lesiak A, Sysa-Jedrzeiowska A, Zakrzewski M, Bogaczewicz J, Stelmach I, Kuna P
    Mediators Inflamm., 2009;2009(0):269541.
    Species: Human
    Sample Types: Serum
  13. Increases in serum TARC/CCL17 levels are associated with progression-free survival in advanced melanoma patients in response to dendritic cell-based immunotherapy.
    Authors: Cornforth AN, Lee GJ, Fowler AW, Carbonell DJ, Dillman RO
    J. Clin. Immunol., 2009;29(5):657-64.
    Species: Human
    Sample Types: Serum
  14. Phenotype of atopic dermatitis subjects with a history of eczema herpeticum.
    Authors: Beck LA, Boguniewicz M, Hata T, Schneider LC, Hanifin J, Gallo R, Paller AS, Lieff S, Reese J, Zaccaro D, Milgrom H, Barnes KC, Leung DY
    J. Allergy Clin. Immunol., 2009;124(2):260-9, 269.e1.
    Species: Human
    Sample Types: Serum
  15. In vitro induction of a dendritic cell phenotype in primary human acute myelogenous leukemia (AML) blasts alters the chemokine release profile and increases the levels of T cell chemotactic CCL17 and CCL22.
    Authors: Olsnes AM, Ryningen A, Ersvaer E, Bruserud Ø
    J. Interferon Cytokine Res., 2008;28(5):297-310.
    Species: Human
    Sample Types: Cell Culture Supernates
  16. Development of an in vitro potency bioassay for therapeutic IL-13 antagonists: the A-549 cell bioassay.
    Authors: Miller R, Sadhukhan R, Wu C
    J. Immunol. Methods, 2008;334(1):134-41.
    Species: Human
    Sample Types: Cell Culture Supernates
  17. Comparison of serum markers for allergic bronchopulmonary aspergillosis in cystic fibrosis.
    Authors: Latzin P, Hartl D, Regamey N, Frey U, Schoeni MH, Casaulta C
    Eur. Respir. J., 2007;31(1):36-42.
    Species: Human
    Sample Types: Serum
  18. Proteomics analysis of Hodgkin lymphoma: identification of new players involved in the cross-talk between HRS cells and infiltrating lymphocytes.
    Authors: Ma Y, Visser L, Roelofsen H, de Vries M, Diepstra A, van Imhoff G, van der Wal T, Luinge M, Alvarez-Llamas G, Vos H, Poppema S, Vonk R, Van Den Berg A
    Blood, 2007;111(4):2339-46.
    Species: Human
    Sample Types: Cell Culture Supernates
  19. Specific recruitment of regulatory T cells into the CSF in lymphomatous and carcinomatous meningitis.
    Authors: Haas J, Schopp L, Storch-Hagenlocher B, Fritzsching B, Jacobi C, Milkova L, Fritz B, Schwarz A, Suri-Payer E, Hensel M, Wildemann B
    Blood, 2007;111(2):761-6.
    Species: Human
    Sample Types: CSF
  20. Functional diversity of T-cell subpopulations in subacute and chronic hypersensitivity pneumonitis.
    Authors: Barrera L, Mendoza F, Zuniga J, Estrada A, Zamora AC, Melendro EI, Ramirez R, Pardo A, Selman M
    Am. J. Respir. Crit. Care Med., 2007;177(1):44-55.
    Species: Human
    Sample Types: BALF
  21. Circulating thymus- and activation-regulated chemokine/CCL17 is a useful biomarker for discriminating acute eosinophilic pneumonia from other causes of acute lung injury.
    Authors: Miyazaki E, Nureki S, Ono E, Ando M, Matsuno O, Fukami T, Ueno T, Kumamoto T
    Chest, 2007;131(6):1726-34.
    Species: Human
    Sample Types: BALF
  22. Chemokines indicate allergic bronchopulmonary aspergillosis in patients with cystic fibrosis.
    Authors: Hartl D, Latzin P, Zissel G, Krane M, Krauss-Etschmann S, Griese M
    Am. J. Respir. Crit. Care Med., 2006;173(12):1370-6.
    Species: Human
    Sample Types: Serum
  23. CD16+ monocyte-derived macrophages activate resting T cells for HIV infection by producing CCR3 and CCR4 ligands.
    Authors: Ancuta P, Autissier P, Wurcel A, Zaman T, Stone D, Gabuzda D
    J. Immunol., 2006;176(10):5760-71.
    Species: Human
    Sample Types: Cell Culture Supernates
  24. Der p, IL-4, and TGF-beta cooperatively induce EGFR-dependent TARC expression in airway epithelium.
    Authors: Heijink IH, Marcel Kies P, van Oosterhout AJ, Postma DS, Kauffman HF, Vellenga E
    Am. J. Respir. Cell Mol. Biol., 2006;36(3):351-9.
    Species: Human
    Sample Types: Cell Culture Supernates
  25. Glucocorticoid-induced tumour necrosis factor receptor (GITR) and its ligand (GITRL) in atopic dermatitis.
    Authors: Baumgartner-Nielsen J, Vestergaard C, Thestrup-Pedersen K
    Acta Derm. Venereol., 2006;86(5):393-8.
    Species: Human
    Sample Types: Plasma
  26. Serum levels of cutaneous T-cell attracting chemokine (CTACK) as a laboratory marker of the severity of atopic dermatitis in children.
    Authors: Hon KL, Leung TF, Ma KC, Li AM, Wong Y, Fok TF
    Clin. Exp. Dermatol., 2004;29(3):293-6.
    Species: Human
    Sample Types: Serum
  27. Increased macrophage-derived chemokine in exhaled breath condensate and plasma from children with asthma.
    Authors: Leung TF, Wong GW, Ko FW, Lam CW, Fok TF
    Clin. Exp. Allergy, 2004;34(5):786-91.
    Species: Human
    Sample Types: Plasma
  28. CSF chemokine levels in relapsing neuromyelitis optica and multiple sclerosis.
    Authors: Narikawa K, Misu T, Fujihara K, Nakashima I, Sato S, Itoyama Y
    J. Neuroimmunol., 2004;149(1):182-6.
    Species: Human
    Sample Types: Serum
  29. Thymus and activation-regulated chemokine (TARC/CCL17) produced by mouse epidermal Langerhans cells is upregulated by TNF-alpha and IL-4 and downregulated by IFN-gamma.
    Authors: Xiao T, Fujita H, Saeki H, Mitsui H, Sugaya M, Tada Y, Kakinuma T, Torii H, Nakamura K, Asahina A, Tamaki K
    Cytokine, 2003;23(4):126-32.
    Species: Human
    Sample Types: Serum
  30. Helper T-lymphocyte-related chemokines in healthy newborns.
    Authors: Leung TF, Ng PC, Tam WH, Li CY, Wong E, Ma TP, Lam CW, Fok TF
    Pediatr. Res., 2003;55(2):334-8.
    Species: Human
    Sample Types: Serum
  31. Characterization of monocyte subtypes in the allergic form of atopic eczema/dermatitis syndrome.
    Authors: Novak N, Allam P, Geiger E, Bieber T
    Allergy, 2002;57(10):931-5.
    Species: Human
    Sample Types: Serum
  32. Skewing of cytotoxic activity and chemokine production, but not of chemokine receptor expression, in human type-1/-2 gamma delta T lymphocytes.
    Authors: D&amp;amp;apos;Ambrosio D
    Eur. J. Immunol., 2002;32(10):2934-43.
    Species: Human
    Sample Types: Cell Culture Supernates
  33. Elevated levels of thymus and activation-regulated chemokine (TARC) in pleural effusion samples from patients infested with Paragonimus westermani.
    Authors: Matsumoto N, Mukae H, Nakamura-Uchiyama F, Ashitani JI, Abe K, Katoh S, Kohno S, Nawa Y, Matsukura S
    Clin. Exp. Immunol., 2002;130(2):314-8.
    Species: Human
    Sample Types: Pleural Effusion
  34. A cytokine-to-chemokine axis between T lymphocytes and keratinocytes can favor Th1 cell accumulation in chronic inflammatory skin diseases.
    Authors: Albanesi C, Scarponi C, Sebastiani S, Cavani A, Federici M, Sozzani S, Girolomoni G
    J. Leukoc. Biol., 2001;70(4):617-23.
    Species: Human
    Sample Types: Cell Culture Supernates
  35. Clonal Th2 cells associated with chronic hypereosinophilia: TARC-induced CCR4 down-regulation in vivo.
    Authors: de Lavareille A, Roufosse F, Schandene L, Stordeur P, Cogan E, Goldman M
    Eur. J. Immunol., 2001;31(4):1037-46.
    Species: Human
    Sample Types: Serum

FAQs

No product specific FAQs exist for this product, however you may

View all ELISA FAQs

ELISA Controls

Supplemental ELISA Products

Reviews for Human CCL17/TARC Quantikine ELISA Kit

Average Rating: 5 (Based on 1 Review)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%

Have you used Human CCL17/TARC Quantikine ELISA Kit?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Filter by:


Human CCL17/TARC Quantikine ELISA Kit
By Anonymous on 06/27/2019
Application: Sample Tested: Serum

Importance of serum „Thymus and Activation-Regulated Chemokine (TARC) determination in classical Hodgkin lymphoma’s (cHL) patients
Thymus and Activation-Regulated Chemokine (TARC or CCL17) is highly expressed by Hodgkin and Reed-Sternberg cells and secreted into the serum. Therefore it can be a useful tumor marker of classical Hodgkin lymphoma (cHL). Our aim has been to study the value of serum TARC concentrations in the course of treatment, and follow up in patients with cHL. We enrolled 613 patients diagnosed with cHL, who were treated by the National Institute of Oncology, Hungary, between 2011 and 2018. Serum TARC levels were determined with a quantitative sandwich enzyme immunoassay technique (R&D Systems, Biotechne, Minneapolis, MN). Measurements were carried out in 3 month intervals following diagnosis, and 6 month intervals after 3 years. In 241 cases, serum TARC concentrations were determined before therapy, as well. Total number of measurements taken were 2015. Receiver Operating Characteristic (ROC) curve analysis was performed for comparison of healthy controls (n=168) and patients with active disease status before treatment (n=241). The cut-off value was 637 pg/ml with 90.9% sensitivity and 98.2% specificity. During follow-ups the median serum TARC value was 14350 pg/ml in patients with active disease status. In case of complete remission it was 401 pg/ml. ROC curve analysis of active versus complete remission groups showed a high 85.6% sensitivity and 93.7% specificity with a 936 pg/ml cut-off value. Our data confirmed the usefulness of TARC determination in the course of treatment and follow-up. TARC may be a potential marker for early response assessment and may be able to predict potential relapse of the disease. Determination of serum TARC concentrations with high sensitivity and cost-efficacy, is highly recommened for monitoring and at diagnosis of cHL patients.